Anavex has announced significant findings from its phase 2b/3 trial of blarcamesine, an
investigational treatment for early Alzheimer’s disease. The results indicate a
notable reduction in amyloid-ß biomarkers, a critical factor in Alzheimer’s
pathology, and demonstrate the drug’s potential to slow cognitive decline.

The multicenter, randomized, double-blind study involved 508 participants across five countries,
who received either blarcamesine or a placebo for 48 weeks. The trial’s primary
endpoints were assessed using the Alzheimer’s Disease Assessment Scale-Cognitive
(ADAS-Cog) and the Alzheimer’s Disease Cooperative Study-Activities of Daily
Living (ADCS-ADL) subscales. The findings revealed statistically significant
improvements in these metrics for patients treated with blarcamesine compared
to those who received the placebo. 

Marwan Noel Sabbagh, MD, a prominent neurologist, emphasized the trial’s impact, stating,
“There is hope that new therapies targeting Alzheimer beyond amyloid could slow
disease progression for many people.” His comments underscore the growing
optimism surrounding Anavex’s innovative approach. 

Among the secondary outcomes, MRI scans showed a significant reduction in pathological brain
atrophy for treated patients. Furthermore, biomarkers like the plasma Aβ42/40
ratio showed positive changes, reinforcing the drug’s anti-amyloid effects. 

However, the study did note some treatment-emergent adverse events, predominantly dizziness, which
was generally transient and mild to moderate in severity. Despite these side
effects, the safety profile of blarcamesine remains favorable. 

Christopher U Missling, PhD, CEO of Anavex Life Sciences, expressed gratitude to all study participants and highlighted the
company’s commitment to advancing Alzheimer’s treatment. “Anavex’s clinical
development is a testament to our determination to follow the science,” he stated. 

With these encouraging results, Anavex Life Sciences is poised to continue its research
into blarcamesine, potentially offering a new, effective treatment option for
Alzheimer’s disease. Read this article for more information. 

Follow their page on https://twitter.com/AnavexLifeSci